DXCM(DexCom, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| 毛利润 | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B |
| 营业利润 | $265.80M | $391.20M | $597.70M | $600.00M | $911.80M |
| 净利润 | $216.90M | $341.20M | $541.50M | $576.20M | $836.30M |
| 经营现金流 | $442.50M | $669.50M | $748.50M | $989.50M | $1.44B |
| 自由现金流 | $53.30M | $304.70M | $511.90M | $630.70M | $1.08B |
| 摊薄每股收益 | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |